Brahme N N, Szabo E
Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
Clin Pharmacol Ther. 2017 May;101(5):575-577. doi: 10.1002/cpt.566. Epub 2016 Dec 29.
Cancer is a highly heterogeneous disease, both between and within different target organs. Precision cancer prevention requires understanding the molecular pathways leading to cancer on a "per-person" level, identification of individuals most at risk for developing cancer, and tailoring interventions to accommodate pathogenesis, risk, and individual responses to interventions. This commentary will discuss how an investment in precision prevention research can accelerate cancer prevention agent development-the key to reducing cancer incidence and mortality.
癌症是一种高度异质性疾病,在不同靶器官之间以及同一靶器官内部均如此。精准癌症预防需要在“个体层面”了解导致癌症的分子途径,识别最易患癌症的个体,并根据发病机制、风险以及个体对干预措施的反应来定制干预措施。本评论将讨论对精准预防研究的投入如何能够加速癌症预防药物的开发,而这是降低癌症发病率和死亡率的关键。